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Abstract 
Menopausal estrogen loss leads to an increased bone loss. Soy isoflavones can act as 
selective estrogen receptor modulators, their role in bone turnover is unclear. The 
primary outcome was assessing changes in plasma bone turnover markers. The 
secondary outcomes were assessing changes in cardiovascular risk markers including 
insulin resistance, blood pressure and lipid profile. We performed a double blind 
randomised parallel study where 200 women within 2 years after the onset of their 
menopause were randomised to 15 g soy protein with 66mg isoflavone (SPI) or 15 g 
soy protein alone (SP), daily for 6 months. 
There was a significant reduction in type I collagen crosslinked Beta C-telopeptide 
(βCTX) (bone-resorption marker) with SPI supplementation (0.40 ± 0.17 vs. 0.15 ± 
0.09µg/L; p<0.01) compared to SP supplementation (0.35 ± 0.12 vs. 0.35 ± 0.13µg/L; 
p=0.92) after 6 months.  There was also a significant reduction in type I procollagen-
N-propeptide (P1NP) (bone-formation marker) with SPI supplementation (50.5 ± 25.0 
vs. 34.3 ± 17.6µg/L; p<0.01), more marked between 3 and 6 month.   
Following SPI there was a significant reduction in fasting glucose, fasting insulin, 
insulin resistance and systolic blood pressure whereas no significant changes in these 
parameters was observed with SP.  There were no significant changes in fasting lipid 
profile and diastolic blood pressure with either preparation.  There was a significant 
increase in TSH and reduction in free thyroxine (p<0.01) with SPI supplementation 
though free tri-iodothyronine was unchanged.   
In conclusion, soy protein with isoflavones may confer a beneficial effect on bone 
health, analogous to the mode of action of anti-resorptive agents albeit to a less 
magnitude. There was a significant improvement of cardiovascular risk markers, but a 
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significant increase in TSH and reduction in free thyroxine after SPI supplementation 
indicating a detrimental effect on thyroid function.   
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Background 
Postmenopausal estrogen loss leads to osteoporosis that is a skeletal disorder 
characterized by compromised bone strength, resulting in nearly 9 million fractures 
annually worldwide.(1) The annual rates and cumulative amounts of bone mineral 
density (BMD) loss is greater one year prior to its onset and through two years after 
the final menstrual period (transmenopause) than those occurring between two and 
five years after the final menstrual period (postmenopause).(2) 
Epidemiological studies generally suggest a positive association between soy 
consumption and BMD,(3) but it is not known if this is due to the soy phytoestrogens 
that have effects similar to estrogen, due to the soy protein alone, or requires a 
combination of both.  Phytoestrogens are a broad group of compounds that consist of 
isoflavones, lignans and coumestans. Of these, isoflavones are heterocyclic phenols 
the main constituents of which are genistein, daidzein and glycitein.  They have a 
similar structure to 17 beta estradiol and have been shown to have biological activity 
exerting estrogen-like effects both in vitro and in vivo.  Estrogen increases BMD and 
has a protective effect on bones in females.  
Previous studies evaluating the effects of soy isoflavones on bone  health have shown 
conflicting results likely due to differences in the soy preparations and the 
comparators used, the study population chosen and the use of bone densitometry as an 
outcome measure that is unable to detect early or small treatment effects. Bone 
turnover markers (BTMs) are biomarkers for fracture risk that have been used for the 
diagnosis and evaluation of therapy effects on osteoporosis, and include both bone 
resorption markers (e.g. type I collagen crosslinked Beta C-telopeptide (βCTX)) and 
bone formation markers (e.g. type I procollagen-N-propeptide (PINP)). 
It was hypothesised by us that any soy effect would be apparent within the first two 
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years of the menopause when there was maximal bone loss, and therefore this 
randomised, double blind, parallel study was undertaken during this timeframe in 
women within two years of their last menstrual period using the BTM outcome 
measures of βCTX and P1NP. BTMs rather than BMD were utilized as it has 
previously been shown that it can take two years before conventional anti-resorptive 
treatment leads to a change in BMD sufficient to exceed the precision error of the test 
or least significant change.(4) 
Materials and methods 
Two hundred Caucasian women within two years of the onset of their menopause 
(FSH greater than 20 mU/L and amenorrhoea for one year) were recruited after 
screening 334 women who responded to newspaper advertisements. Subjects were 
taking either no medication or on stable medications for at least three months and did 
not smoke. Women who were taking medication that could interfere with bone 
metabolism including steroids, bisphosphonates, thyroxine or hormone replacement 
therapy were excluded. Women with significant hepatic or renal impairment, who 
were allergic to soy products and those who had antibiotic exposure in the three 
months prior to the study were also excluded.  
They were randomised into groups and either administered SPI (15 g soy protein with 
66 mg of isoflavones) (100 women) or SP (15 g soy protein alone, isoflavone free) 
(100 women) daily for a period of six months.   
The primary outcome of this study was assessing any change in plasma βCTX and 
PINP. The secondary outcome for this study was assessing any change in 
cardiovascular risk markers including insulin resistance, lipids, and hsCRP since in 
some studies soy has been shown to have a beneficial effect on these markers.  There 
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is some evidence to show that soy could have an effect on thyroid function hence 
changes in thyroid function tests were assessed although was not planned apriori.   
During study visits (baseline, three months and six months), subjects were instructed 
to maintain their normal level of physical activity throughout the study. In addition, 
subjects were required to avoid food products containing soy, alcohol, vitamin or 
mineral supplementation, and over-the-counter medications. Dietary reinforcement 
was undertaken at each visit, together with measurement of serum isoflavone 
concentrations to ensure compliance. There was telephone contact by study personnel, 
six and 18 weeks after study visits to ensure compliance. Analysis of compliance with 
the study preparation was undertaken by counting the returned sachets. All subjects 
gave their written informed consent for this study that had been approved by the 
Research Ethics Committee (East Yorkshire & North Lincolnshire Research Ethics 
Committee, ref: 09/1304/45).    
Study product 
A snack bar either containing 7.5 g isolated soy protein powder (Solcon F, Solbar 
Industries, Israel) with 33 mg of isoflavones (SPI) (Sogen 40, Solbar Industries, 
Israel) given twice daily between meals (15 g soy protein and 66 mg of isoflavones 
per day), or 7.5 g of the isolated soy protein  alone given twice daily (15 g soy protein 
per day without isoflavones per day) as control (isoflavone of less than 300 parts per 
billion following serial alcohol extraction, Dishman Ltd, India; assayed by FERA, 
Sand Hutton, UK) (SP). The snack bars were to be eaten twice daily between meals 
for 6 months. The soy protein and the isoflavones were from a single batch that was 
designated for the study. The study bars were specifically prepared and packaged by 
Halo foods, Swindon, UK. Soy bars were identical and had similar macronutrient 
content. 
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Randomisation 
The randomisation was performed by Essential Nutrition Ltd, UK. A computer 
generated randomisation sequence was used to provide balanced blocks of patient 
numbers for each of the two treatment groups. A one-to-one treatment allocation was 
used. Blinding was performed at manufacture and the randomisation code was held by 
Essential Nutrition Ltd. All investigators, study staff, and subjects were blinded to the 
treatment assignment throughout the entire study. Empty wrappers and uneaten bars 
were returned and counted by the study team. If compliance was less than 75% then 
the subject was withdrawn from the study. 
Study measurements 
During the baseline, three months and six month study visits, following an over-night 
fast, anthropometric parameters were measured and blood samples collected. Blood 
pressure was measured after the patients had been seated quietly for at least five 
minutes with the right arm supported at heart level. Blood pressure measurements 
were performed using an automated device (NPB-3900; Nellcor Puritan Bennett, 
Pleasanton, CA) during each study visit. Two readings were obtained at the beginning 
of each visit at least one minute apart and the average of the readings was taken. 
Fasting venous blood samples were collected, separated by centrifugation at 2000 g 
for 15 min at 4oC, and the aliquots stored at -80oC within one hour of collection. 
Plasma glucose was measured using a Synchron DxC analyzer (Beckman-Coulter, 
UK), and serum insulin was assayed using an ultra-sensitive chemiluminescent one-
step immunoenzymetic ‘sandwich’ assay performed on a Unicel DXi Immunoassay 
system (Beckman-Coulter, UK). The coefficient of variation (CV) of this method was 
8%, calculated using duplicate study samples. The analytical sensitivity was 2 
µU/mL.  Insulin resistance was calculated using HOMA-IR (Insulin x glucose)/22.5) 
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(5).  HOMA is a validated surrogate marker for IR that correlates closely with the 
gold standard hyperinsulinaemic euglycaemic clamp (5). Total cholesterol, 
triglycerides, and high-density lipoprotein cholesterol (HDL-C) levels were measured 
enzymatically using a Synchron DxC analyzer (Beckman-Coulter, UK). Low-density 
lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation. 
Analytical performance in terms of imprecision at discreet levels (%CV, Mean) was 
total cholesterol (0.7%, 4.9mmol/L), HDL cholesterol (1.6%, 1.9mmol/L) and 
triglyceride (3.3%, 1.6mmol/L). Serum CRP was measured by the high-sensitivity 
method on a Beckman DXC analyzer. Analytical performance in terms of imprecision 
at discreet levels (%CV, Mean) was (0.9%, 9mg/L).  All thyroid assays were 
performed on an Abbott Architect i4000 immunoassay analyser (Abbott Diagnostics 
Division, UK).  Analytical performance in terms of imprecision at discreet levels 
(%CV, Mean) was free thyroxine (fT4) was (4%, 13.7pmol/L) and that of thyroid 
stimulating hormone (TSH) was (4.2%, 1.32 pmol/L).  
Plasma βCTX was measured using an electrochemiluminescent immunoassay 
(ECLIA) on a Cobas 1600i analyser (Roche Diagnostics, Lewes, UK). Inter/ Intra 
assay coefficient of variation of plasma βCTX was <3% between 0.2 and 1.5 µg/L. 
The assay sensitivity (replicates of the zero standard) was 0.01 µg/L. Plasma P1NP 
was measured using an ECLIA on a Cobas 1600i analyser (Roche Diagnostics, 
Lewes, UK). Inter/ Intra assay CV of plasma P1NP was <3% between 20-600 µg/L. 
The assay sensitivity (replicates of the zero standards) was 8 µg/L. 
The isoflavones in serum were extracted and analysed by Quotient Biosciences, UK 
using isotope-dilution LC-MS/MS (6). LC-MS/MS was conducted using a Sciex 4000 
Qtrap with separation achieved using a C18 column and mobile phases of water and 
acetonitrile, both containing acetic acid. No column switching was used. The 
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calibration range for all analytes was 0.5 ng/mL to 200 ng/mL, with quality control 
samples prepared at low (1.5 ng/mL), medium (80 ng/mL) and high (150 ng/mL) 
concentrations and analysed to confirm the assay performance. Incurred QC samples 
of serum were also run in the sample batches. The assay sensitivity for equol, daidzein 
and genistein were all 0.5 ng/mL. The inter assay CVs were less than 6.8% for 
daidzein, less than 6.1% for genistein and less than 7.4% for equol. 
Sample size calculation 
The study was powered for changes in βCTX (SD=0.20 µg/L, medium effect 
size=0.67, minimum detectable difference of 0.13 µg/L) and P1NP (SD=115 µg/L, 
minimum detectable difference=76 µg/L) based on the study of 
Charatcharoenwitthaya et al (7) using N-query software, for 95% power, 5% 
significance (2-tailed), 100 women were required per group including a 40% dropout 
rate.  
Statistical analysis 
Continuous data was summarised by the median (25th/75th centiles) and categorical 
data by percentages (%). Given this was a randomised controlled trial, baselines were 
not compared statistically. Box and whisker plots show data distributions. The line in 
the middle of the box is the median: the bottom and top of the box are the 25th and 
75th centiles respectively, while the dots are observations that lie outside the quartiles.  
For each group (SPI and SP) separately a paired difference (six-months minus 
baseline) of means was calculated. These two statistics are summarised as a paired 
mean across all patients in tables. The two paired means were then compared using an 
independent t-test the p-value is the probability of the difference of the difference 
being a false positive. This is referred to the tables as the 'difference of the difference' 
and 95% confidence interval gives the precision of the difference of the difference in 
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the tables. The Stata statistical computer package was used to analyse the data 
(StataCorp. Stata Statistical Software.  Release 13. College Station, Texas, 2013). 
 
Results 
Two hundred Caucasian women within two years of their menopause (FSH greater 
than 20 mU/L and amenorrhoea for one year) were recruited after screening 334 
women who responded to newspaper advertisements. In total 60 women in the SPI 
group and 60 women in the SP group completed six months of the study, with an 
overall dropout rate of 39% (Figure 1).  Their characteristics and reasons for drop outs 
are described in Table 1. 
The baseline anthropometric, metabolic, plasma isoflavone levels and BTMs were 
comparable between the two groups (Table 2).  
The mean βCTX was significantly lower after 6 months of SPI supplementation 
compared to SP supplementation (p<0.01: Figure 2a). There was also a significant 
reduction of P1NP with SPI supplementation for 6 months compared to SP 
supplementation (p<0.01:Table 2) and was more pronounced between 3 and 6 months 
(Figure 2b). 
There was a significant reduction in the mean metabolic parameters including fasting 
glucose, fasting insulin and HOMA-IR in the SPI group compared to the SP group 
after six months (Table 3). There were no significant changes observed in lipid 
parameters (total cholesterol, LDL-C, HDL-C and triglycerides) and hsCRP between 
the SPI and SP administered groups. There was a significant reduction in systolic 
blood pressure with six months of SPI supplementation but no change with SP 
supplementation.  There were no changes in diastolic blood pressure after either SPI 
or SP supplementation.  (Table 3) 
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There was a significant increase in mean TSH (mean (SD) (1.58 (0.93) vs. 2.61 (1.24) 
mU/L, p<0.01) and corresponding significant reduction in mean fT4 (13.5 (2.2) vs. 
11.2 (1.8) pmol/L, p<0.01) from baseline to three months.  There were no significant 
changes in TSH and fT4 between three and six months.  There were also no 
significant changes in the fT3 between both preparations (Table 3). 
There was a significant increase in mean daidzein, genistein and equol in the SPI 
administered group compared to the SP group (Table 3).  
There were no significant changes in endometrial thickness before and after either SPI 
or SP supplementation. 
Discussion 
This study showed that soy with isoflavones had a significant beneficial effect on both 
BTMs and on cardiovascular risk factors including systolic blood pressure, fasting 
glucose, fasting insulin and insulin resistance compared to isoflavone-free soy protein 
in women whose bone loss was maximal in the first 2 years of their menopause. There 
was also a detrimental effect on thyroid function with a decrease in serum T4 and an 
increase in serum TSH with a combination of soy protein and isoflavones in this 
group of women.  This study is the first to use a soy preparation that was truly 
isoflavone free that could determine the contribution to any effect by solely the soy 
protein.  There were no significant treatment effects attributed to soy protein alone at 
either at 3 or 6 months compared to baseline, suggesting that the soy protein alone is 
inactive on these parameters.   
An initial effect on osteoclast function as seen by the changes in P1NP followed by 
decreased osteoblast function, as seen by the changes in βCTX, found in the current 
study suggests isoflavones may have beneficial effects on bone health. There is an 
early phase of predominantly trabecular bone loss following menopause associated 
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with the decrease in oestrogen (8). The annual rates and cumulative amounts of bone 
mineral density loss is greater one year prior through two years after the final 
menstrual period (transmenopause) than those occurring between two and five years 
after the final menstrual period (postmenopause) (2). The rapid bone loss during early 
postmenopausal years is associated with marked increases in biochemical markers of 
bone resorption and due to the coupling of bone resorption and bone formation, bone 
formation also increases over time (9, 10).  The effect of hormone replacement 
therapy on postmenopausal women is mainly a reduction in bone resorption and a 
secondary decrease in bone formation, reflecting a decrease in the activation 
frequency of new bone-remodelling units (11, 12).  Soy isoflavones have a chemical 
structure similar to oestrogen, bind to and transactivate estrogen receptors (ER) (13-
15) and exert oestrogen-like effects both in vitro and in vivo (16).  The significant 
early reduction in bone resorption markers followed by later reduction in bone 
formation markers in the current study suggests the mechanism of soy protein and 
isoflavones in bone could be similar to oestrogen replacement therapy.  A similar 
pattern of initial reduction in bone resorption markers followed by bone formation 
markers is also seen with the potent anti-resorptive agents bisphosphonates and 
denosumab, although to a lesser magnitude.(17) 
Very few randomised controlled trials on soy isoflavones effects on bone have 
contained data for βCTX and P1NP, and those reported have generally not detected 
signiﬁcant effects of soy isoﬂavone supplements on these bone turn over markers.(18) 
The heterogeneity of trial results are likely to be a combination of underpowered 
clinical trials and differences in habitual dietary intake of soy isoﬂavones,(19) the 
variable interval since the onset of menopause(20) as well as the chemical forms and 
proportions of individual soy isoﬂavones.(21) The current study sought to minimize 
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these variables by investigating a homogeneous large study population of women who 
were likely to be at maximal bone turnover by being within the first two years of their 
menopause. Bone densitometry was not performed as it is not able to detect early or 
small treatment effects with soy isoflavones over such a short period since the margin 
of error with bone densitometry is high and would require larger numbers to pick up 
significant changes and a longer duration of treatment.   
There was a significant improvement in glucose metabolism with a reduction in both 
insulin and glucose after combined soy protein and isoflavone supplementation. These 
data are in accord with the reported pharmacological action of soy on glycaemic 
control in diabetes, including the inhibition glucose uptake at the intestinal brush 
border through a α-glucosidase inhibitor action, tyrosine kinase inhibitory actions, 
changes in insulin receptor numbers and affinity, intracellular phosphorylation, and 
alterations in glucose transport.(22) The effect on insulin may be mediated by an 
estrogenic effect on insulin sensitivity and glucose uptake and through activation of 
the nuclear peroxisome Proliferator-Activated Receptors (PPAR) that may modulate 
insulin action;(23) PPAR agonists have also been shown to modulate osteoclast 
function that may have contributed to the BTM changes reported.(24) In addition, soy 
has been shown to inhibit insulin secretion from pancreatic β cells.(25) 
This study is the first to use a control soy preparation that was truly isoflavone free 
and as it showed no treatment effects it suggests soy protein alone is inert in relation 
to bone health. There were no changes in body weight after 24 weeks of soy, 
suggesting that the reduction in insulin resistance was independent of the action of 
soy fiber that might enhance satiation and hence induce weight loss.  
There were no changes in any of the lipid parameters by the soy preparations, a 
finding that was discrepant to some(26) but not in all studies.(25) A recent meta-
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analysis suggested that soy isoflavones significantly reduced total cholesterol and 
LDL-C but do not change HDL-C.(27) These differences may be attributed to the 
basal lipid profile or different study designs and isoflavones composition with 
glucoside instead of aglycone forms. There was a significant reduction in systolic 
blood pressure within six months of SPI supplementation but no change with SP 
supplementation.  There were no changes in diastolic blood pressure with either after 
SPI or SP supplementation.  
There was a significant increase in TSH and reduction in fT4 with 12 weeks of 
combined soy protein and isoflavone supplementation where as no significant changes 
between three and six months. This suggests that the maximal effect of SPI was in the 
first three months, which then plateaued, rather than a continual reduction.  There 
were no significant changes in TSH and fT4 with SP supplementation. These findings 
are in accord with an observational cohort showing high consumption of soya was 
associated with elevated TSH concentration in women.(28) Soy consumption is 
associated with thyroid disorders such as hypothyroidism, goitre, and autoimmune 
thyroid disease.(29) In vitro studies have demonstrated that isoflavones inhibit thyroid 
peroxidase (TPO), and inhibit iodide.(30) However, other studies using different 
preparations for up to 3 years have not shown changes in thyroid hormones.(31) In 
patients with subclinical hypothyroidism, the soy protein and isoflavone combination 
has been shown to increase the risk of developing overt hypothyroidism.(32) These 
data suggests that a synergistic matrix of soy protein and isoflavones is needed to 
maximise the effects rather than either soy protein or isoflavone alone.(25, 33)  In the 
current study, where all patients had normal thyroid function tests at baseline, none of 
the patients developed subclinical or overt hypothyroidism. There was also no 
significant change in fT3 with either SPI or SP supplementation.  The statistically 
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significant differences in the concentrations of most markers between zero and six 
months were present within the first three months of the study with the exception of 
PINP where the change was only apparent at six months.   
Studies of isoflavones intakes in Western countries indicate an average daily intake of 
approximately 2 mg isoflavones, vegetarians have a higher daily isoflavone intake of 
16 mg and Asian population consuming high soy diet or people consuming soy 
supplements have a daily isoflavone intake of around 50-90 mg.(34) The isoflavone 
concentrations used in this study reflected the daily intake of an Asian population 
consuming high soy diet or people consuming soy supplements. 
As anticipated the drop out was around 40% so that the power of study was not 
compromised. The most frequent reasons for participant withdrawal in both groups 
are attributable to non-compliance due to palatability, comparable to other nutrition 
and medication trials in patients with osteoporosis.(35) The group who dropped out 
was not significantly different from the group who completed the study. There was a 
significant increase in plasma isoflavone concentrations with SPI confirming 
compliance and isoflavone absorption, whilst there was no change from baseline in 
plasma isoflavones in the SP excluding exogenous isoflavones ingestion.   
In conclusion, this study suggests the consumption of soy with isoflavones may have 
a beneficial effect on bone health where there was a significant decrease in bone turn 
over markers of resorption and formation after supplementation with 15 g soy protein 
with isoflavones for six months. An initial decrease on osteoclast function followed 
by a decrease in osteoblast function appears to be the mechanism of SPI action though 
it is unclear if this translates to a clinical benefit. There was no significant change in 
BTMs with 15 g soy protein alone over six months.  
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Table 1 
Reasons for withdrawal in each group 
 
 SPI group 
baseline to 3 
months 
(n=19) 
SPI group 
3 to 6 months 
(n=21) 
 
SP group 
3 to 6 months 
(n=25) 
 
SP group 
3 to 6 months 
(n=15) 
Age median 
(25th/75th 
centiles) years 
52 (50,55) 52 (50,54) 53 (50,55) 53 (50,55)  
Body mass 
index (kg/m2) 
25.9 (23.9, 30.9 25.8 (24.2, 31.2) 26.5 (24.9, 31.0) 26.6 (24.3, 31.2) 
Reasons for withdrawal 
Lost to follow 
up 
4 10 7 8 
Non-
compliance 
13  11  
Post 
menopausal 
bleeding 
1  1  
Intolerance to 
soy bar 
1 8 3 5 
Antibiotic use  2 3 1 
Started 
hormone 
replacement 
therapy 
 1  1 
SPI (15g soy protein with 66mg of isoflavones); SP (15g soy protein alone isoflavone free) 
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Table 2. Baseline anthropometric, hormonal and biochemical measurements 
between the soy protein with (SPI) and without (SP) isoflavones.  
 
Parameters (units) (normal 
range) 
SPI (n=100) SP (n=100) 
Age (years) 52 (49, 56) 52 (50, 55) 
Body mass index (kg/m2) 26.3 (24.3, 30.7) 24.6 (22.7, 28.4) 
Systolic blood pressure (mmHg) 121 (110, 137) 128 (113, 141) 
Diastolic blood pressure (mmHg) 77 (69, 88) 79 (72, 83) 
TSH (mU/L) (0.35 - 4.7) 1.5 (0.9, 2.2) 1.6 (0.9, 2.3) 
fT4 (pmol/L) (7.8 – 21) 13 (13, 15) 13 (12, 14) 
fT3 (pmol/L) (3.8 – 6) 4.6 (4.3, 5.1) 4.7 (4.3, 4.9) 
aFasting glucose (mg/dL)  90 (86.4, 99.0) 86.4 (82.8, 93.6) 
bFasting insulin (µIU/mL) 4.6 (3.4, 6.7) 4.4 (3.2, 7.4) 
HOMA-IR 1.0 (0.7, 1.5) 0.9 (0.7, 1.6) 
hs CRP (mg/L) (0 – 8) 1.3 (0.6, 2.2) 1.3 (0.9, 2.7) 
cTC (mmol/L)  5.98 (5.38, 6.54) 5.66 (4.98, 6.37) 
LDL-C (mmol/L) 3.3 (2.9, 3.9) 3.3 (2.7, 3.9) 
HDL-C (mmol/L) 1.66 (1.45, 1.88) 1.70 (1.46, 2.10) 
dTriglycerides (mmol/L) 1.08 (0.85, 1.36) 1.08 (0.84, 1.33) 
βCTX (µg/L) (0.1 – 0.5) 0.38 (0.28, 0.48) 0.34 (0.25, 0.46) 
P1NP (µg/L) (19-69) 49.4 (34.7, 57.7) 41.4 (31.5, 50) 
Daidzein (ng/mL)  0.73 (0.49, 2.37) 0.82 (0.49, 2.65) 
Genistin (ng/mL) 1.43 (0.56, 4.2) 1.66 (0.71, 6.98) 
Equol (ng/mL) 0.49 (0.47, 0.51) 0.49 (0.46, 0.54) 
FSH (IU/L)  77 (57, 97) 71 (49, 89) 
LH (IU/L)  32 (25, 42) 29 (27, 38) 
 
SPI (15 g soy protein with 66 mg of isoflavones); SP (15 g soy protein alone isoflavone free) 
Data given as Mean (SEM) 
aTo convert values for glucose to milligrams per deciliter, divide by 0.056.  
bTo convert values for insulin to picomoles per liter, multiply by 6.  
cTo convert values for cholesterol to milligrams per deciliter, divide by 0.0259. 
dTo convert values for triglycerides to milligrams per deciliter, divide by 0.0113.  
TC - Total cholesterol; LDL-C - LDL-cholesterol; HDL-C - HDL cholesterol; TG-Triglycerides 
HOMA-IR – Homeostasis model of assessment – insulin resistance 
hs CRP – highly sensitive C-reactive protein 
TSH – thyroid stimulating hormone 
fT4 – free thyroxine 
fT3 – free tri-iodo thyronine 
βCTX  - collagen type 1 cross-linked Beta C-telopeptide  
P1NP - propeptide of type I collagen, FSH – follicle stimulating hormone, LH – Luteinising hormone
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Table 3. Comparison between SPI and SP supplementation at end of study of metabolic and hormonal factors.   
Parameter 
SPI SP Difference of the 
difference 
(95% CI) 
p-value Baseline 
Mean (SD) 
6 months 
Mean (SD) 
Difference 
(6 mo – baseline) 
Baseline 
Mean (SD) 
6 months 
Mean (SD) 
Difference 
(6 mo – baseline) 
Anthropometric parameters 
Body mass index  
(kg/m2) 
27 (4.6) 27.3 (4.4) 0.37 26.7 (7.0) 27 (6.9) 0.15 0.2 (-0.09,0.53) 0.17 
Systolic blood 
pressure (mmHg) 
125 (20.2) 121.2 (14.9) -3.2 124.6 (18.8) 123.4 (16) -0.8 -2.5 (-4.2,-1.9) <0.01 
Diastolic blood 
pressure (mmHg) 
77 (13.8) 76.8 (9.4) -0.6 77.2 (10.9) 77.4 (11.6) 0.2 -0.8 (-5.2,3.4) 0.68 
Lipid parameters 
TC  
(mmol/L) 
5.8 (0.9) 5.8 (0.9) 0 5.8 (0.8) 5.7 (0.8) -0.15 0.2 (-0.07,0.47) 0.15 
LDL-C  
(mmol/L) 
3.65 (0.7) 3.6 (0.6) -0.15 3.65 (0.9) 3.57 (0.75) -0.10 -0.16 (-0.65,0.72) 0.47 
HDL-C  
(mmol/L) 
1.68 (0.94) 1.62 (0.36) -0.05 1.78 (0.42) 1.65 (0.39) -0.23 -0.37 (-1.28,0.52) 0.39 
Triglycerides  
(mmol/L) 
1.16 (0.54) 1.22 (0.71) 0.09 1.18 (0.57) 1.27 (0.91) 0.09 -0.12 (-0.31,0.06) 0.20 
hs CRP  
(mg/L) 
1.65 (1.55) 0.69 (0.92) -0.96 2.65 (4.49) 2.1 (2.27) -0.5 -0.46 (-1.6,0.58) 0.38 
Glycemic parameters 
Fasting glucose  
(mmol/L) 
5.2 (0.7) 4.4 (0.5) -0.7 5.1 (1.6) 5.0 (0.9) -0.10 -0.7 (-1,-0.4) <0.01 
Fasting insulin  
(µIU/mL) 
5.78 (3.59) 2.64 (1.89) -3.1 5.65 (3.74) 5.82 (3.7) 0.11 -3.25 (-4.-2.43) <0.01 
HOMA-IR 1.39 (1.03) 0.52 (0.4) -0.86 1.43 (1.77) 1.37 (1.42) -0.04 -0.82 (-1.07,-0.56) <0.01 
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Bone turn over markers 
βCTX (µg/L) 0.40 (0.17) 0.15 (0.09) -0.25 0.35 (0.12) 0.35 (0.13) 0.01 -0.26 (-0.31,-0.21) <0.01 
P1NP (µg/L) 50.5 (25) 34.3 (17.6) -16.4 43.3 (15.9) 45.7 (17.7) 2.3 -18.8 (-25.2,-1.2) <0.01 
Thyroid function tests 
TSH  
(mU/L) 
1.58 (0.93) 2.62 (1.26) 1 1.80 (1) 1.80 (1.15) 0 1 (0.6,1.3) <0.01 
fT4  
(pmol/L) 
13.5 (2.2) 11.5 (1.4) -2.2 13.5 (1.8) 12.6 (2.4) -0.8 -1.4 (-2.1,-0.6) <0.01 
fT3  
(pmol/L) 
4.9 (1.8) 5 (2.5) 0.10 4.6 (0.5) 4.5 (0.5) -0.11 0.12 (-0.25,0.51) 0.5 
Plasma isoflavone levels  
Daidzein  
(ng/mL) 
4.49(18.2) 17.8(23.7) 13.3 5.4(19.8) 2.8(6.1) -2.6 15.(6.3,25.6) <0.01 
Genistein  
(ng/mL) 
9.2(32.4) 91.2(107.8) 82 10.1(30) 5.4(12.2) -4.7 86.7(56.6,116.8) <0.01 
Equol  
(ng/mL) 
0.54(0.36) 5.85(11.9) 5.3 0.85(1.69) 0.75(1.29) -0.1 5.4(2.3,8.4) <0.01 
 
Paired difference=6-months-baseline.  Difference of the difference is an unpaired t-test of the paired differences. 
SPI (15g soy protein with 66mg of isoflavones); SP (15g soy protein alone isoflavone free) 
HOMA-IR – Homeostasis model of assessment – insulin resistance; TC - Total cholesterol; LDL-C - LDL-cholesterol; HDL-C - HDL cholesterol; TG-
Triglycerides; hs CRP – highly sensitive C reactive protein 
TSH – thyroid stimulating hormone; fT4 – free thyroxine; fT3 – free tri-iodo thyronine 
Reference ranges: fasting glucose (<7mmol/L), TSH (0.35-4.7mU/L), fT4 (7.8-21pmol/L), fT3 (3.8-6pmol/L ) 
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Figure 1 
 
Flow diagram of participants through the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPI – Soy protein + isoflavone group 
SP – Soy protein without isoflavone group 
 
 
 
 
 
 
 
 
 
 
 
 
Number of women screened 
n=334 
Number of women randomised 
n= 200 (SPI - 100 and SP - 100) 
 
 
 
3 months 
SPI 
n=81 
Drop outs=19 
 
 
 
6 months 
SPI 
n=60 
Drop outs=21 
 
 
 
3 months 
SP 
n=75 
Drop outs=25 
 
 
 
6 months 
SP 
n=60 
Drop outs=15 
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Figure 2A 
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Figure 2 
SPI – Soy protein + isoflavone 
SP – Soy protein alone 
Outliers to the above (either side of the ‘whiskers’) are show as dots. 
Figure 2A.  
Box and whisker plot showing plasma levels of β C-terminal telopeptide (CTX) in 
individuals administered either 30 g soy protein with 66 mg isoflavones (SPI) and 
without isoflavones (SP), at baseline, 3 and 6 months. 
p values  
SPI (baseline – 3 months <0.01; 3 months to 6 months = 0.05) 
SP (baseline – 3 months=0.72; 3 months to 6 months = 0.84) 
Figure 2B.   
Box and whisker plot showing plasma levels of propeptide of type I collagen (PINP) 
in individuals administered either 30 g soy protein with 66 mg isoflavones (SPI) and 
without isoflavones (SP), at baseline, 3 and 6 months. 
p values 
SPI (baseline – 3 months =0.92; 3 months to 6 months = <0.01) 
SP (baseline – 3 months=0.24; 3 months to 6 months = 0.83) 
 
